S. Terence Dunn

S. Terence Dunn

Auto-generated profile, based on publicly available information

S. Terence Dunn

Department of Medicine, Queen's University, Kingston, Canada

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2024 in eClinicalMedicine
Verified
Journal Article
Open access
AMAbhenil Mittal
Abhenil Mittal
MKMyung Sun Kim
Myung Sun Kim
SDShenna Dunn
Shenna Dunn
KWKristin Wright
Kristin Wright
Bishal GyawaliBishal Gyawali
Bishal Gyawali
Patients with cancer expect prolonged life (overall survival, OS) or better life (quality of life, QOL) from cancer treatments. However, majority of new cancer drugs are now being approved not based on improved OS or QOL, but based on surrogate endpoints such as tumor shrinkage or delayed tumor progression. These surrogate endpoints, including their validity as a proxy for overall survival, differ based on disease settings and lines of treatment but in general, most surrogate measures have weak correlation with outcomes that matter to patients. Nevertheless, they are being increasingly used as the basis for regulatory decisions. The current tension in this space is between adoption of surrogate endpoints for early access to cancer drugs versus the need for confirmation that the drugs improve outcomes that matter and not merely improve scan results or surrogate endpoints. In this article, we provide a comprehensive review of surrogate endpoints currently used in oncology trials both in curative and advanced disease settings, including their definition, methodology for validation, existing evidence for their surrogacy, predictive versus prognostic reliability of surrogate endpoints, the promise of surrogate endpoints, their pitfalls, and the way forward. Using a Q&A format, we discuss answers to the most commonly asked questions regarding surrogate endpoints in oncology. Our review answers the following frequently asked questions about surrogate endpoints in oncology: how are surrogate endpoints defined? How are they validated? What is a patient-level versus trial-level surrogate? What are the benefits of using surrogate endpoints? What level of surrogacy is required for regular versus accelerated approval? Are we overusing surrogate endpoints? Should we use surrogate endpoints in adjuvant settings? Can surrogacy be extrapolated from one setting to another? What is the surrogacy of progression-free survival for OS and QOL? Why does PFS not correlated with OS or QOL? Why do regulators rely on surrogate endpoints? We end this article with a proposal on the way forward.

17 February 2018 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
NWNicolas Wentzensen
Nicolas Wentzensen
JWJOAN LESLIE WALKER
JOAN LESLIE WALKER
KSKatie Smith
Katie Smith
MGMichael A Gold
Michael A Gold
RZRosemary Zuna
Rosemary Zuna
MSMark Schiffman
Mark Schiffman
Sensitivity for detection of precancers at colposcopy and reassurance provided by a negative colposcopy are in need of systematic study and improvement. We sought to evaluate whether selecting the appropriate women for multiple targeted cervical biopsies based on screening cytology, human papillomavirus testing, and colposcopic impression could improve accuracy and efficiency of cervical precancer detection. In all, 690 women aged 18-67 years referred to colposcopy subsequent to abnormal cervical cancer screening results were included in the study (ClinicalTrials.gov: NCT00339989). Up to 4 cervical biopsies were taken during colposcopy to evaluate the incremental benefit of multiple biopsies. Cervical cytology, human papillomavirus genotyping, and colposcopy impression were used to establish up to 24 different risk strata. Outcomes for the primary analysis were cervical precancers, which included p16+ cervical intraepithelial neoplasia 2 and all cervical intraepithelial neoplasia 3 that were detected by colposcopy-guided biopsy during the colposcopy visit. Later outcomes in women without cervical intraepithelial neoplasia 2+ at baseline were abstracted from electronic medical records. The risk of detecting precancer ranged from 2-82% across 24 strata based on colposcopy impression, cytology, and human papillomavirus genotyping. The risk of precancer in the lowest stratum increased only marginally with multiple biopsies. Women in the highest-risk strata had risks of precancer consistent with immediate treatment. In other risk strata, multiple biopsies substantially improved detection of cervical precancer. Among 361 women with cervical intraepithelial neoplasia <2 at baseline, 195 (54%) had follow-up cytology or histology data with a median follow-up time of 508 days. Lack of detection of precancer at initial colposcopy that included multiple biopsies predicted low risk of precancer during follow-up. Risk assessment at the colposcopy visit makes identification of cervical precancers more effective and efficient. Not finding precancer after a multiple-biopsy protocol provides high reassurance and allows releasing women back to regular screening.

1 March 1997 in Head & Neck
Verified
Journal Article
Closed access
PDF file
SDS. Terence Dunn
S. Terence Dunn
GCGary D. Clark
Gary D. Clark
TCThomas C. Cannon
Thomas C. Cannon
KMKyung-Whan Min
Kyung-Whan Min

21 September 2013 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
MCMatthew D. Cykowski
Matthew D. Cykowski
RARichard A. Allen
Richard A. Allen
AKAngela C. Kanaly
Angela C. Kanaly
KFKar-Ming Fung
Kar-Ming Fung
RMRoxanne Marshall
Roxanne Marshall
SDS. Terence Dunn
S. Terence Dunn

1 January 2006 in Disease Markers
Verified
Journal Article
Open access
PDF file
CKCory B. Kebert
Cory B. Kebert
JEJune E. Eichner
June E. Eichner
WMWilliam E. Moore
William E. Moore
ESEliot Schechter
Eliot Schechter
TYTakuro Yaoi
Takuro Yaoi
SDS. Terence Dunn
S. Terence Dunn
Numerous studies have investigated the relationship between polymorphisms, in particular 677C‐T and 1298A‐C, of the methylene‐tetrahydrofolate reductase (MTHFR) gene and coronary artery disease (CAD) with conflicting results. This study investigates the potential association of two point mutations in MTHFR, 677C‐T and 1793G‐A, along with other risk factors, with CAD. This is the first hospital‐based study to investigate 1793G‐A in this context. Genotype analysis was performed on 729 Caucasians and 66 African Americans undergoing coronary angiography using a novel PCR‐based assay involving formation of Holliday junctions. Allelic frequencies for 677C‐T were 66.2% C and 33.8% T for Caucasians and 90.9% C and 9.1% T for African Americans. With respect to the 1793G‐A polymorphism, allelic frequencies were 94.7% G and 5.3% A for Caucasians and 99.2% G and 0.8% A for African Americans. Disease associations were examined in the Caucasian patients due to their greater genotype variability and larger number in the patient cohort. Results suggest that neither 677CT heterozygotes (OR‐1.36; 95% CI 0.95 to 1.96) nor mutant homozygotes (OR‐0.73; 95% CI 0.44 to 1.20) have either an increased or decreased risk for CAD compared to the 677CC genotype. Likewise, the 1793GA genotype did not demonstrate a statistically significant association with CAD compared to 1793GG patients (OR‐0.79; 95% CI 0.47 to 1.33). Mean homocysteine levels (μmol/L) increased from normal to mutant for 677C‐T (677CC: 10.2; 677CT: 11.0; 677TT: 11.6) and normal to heterozygous in 1793G‐A (1793GG: 10.7; 1793GA: 11.5). These MTHFR polymorphisms did not contribute to the prediction of clinically defined CAD in Caucasians.